Veru Gestion

Gestion contrôle des critères 3/4

Le PDG Veru est Mitch Steiner, nommé en Oct2016, a un mandat de 8.08 ans. La rémunération annuelle totale est $ 4.71M, composée du salaire de 18.4% et des bonus 81.6%, y compris les actions et options de la société. détient directement 4.84% des actions de la société, d'une valeur de € 4.64M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.2 ans et 3.9 ans.

Informations clés

Mitch Steiner

Directeur général

US$4.7m

Rémunération totale

Pourcentage du salaire du PDG	18.4%
Durée du mandat du directeur général	8.1yrs
Propriété du PDG	4.8%
Durée moyenne d'occupation des postes de direction	6.2yrs
Durée moyenne du mandat des membres du conseil d'administration	3.9yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Mitch Steiner a-t-elle évolué par rapport aux bénéfices de Veru?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$37m
Mar 31 2024	n/a	n/a	-US$39m
Dec 31 2023	n/a	n/a	-US$63m
Sep 30 2023	US$5m	US$866k	-US$93m
Jun 30 2023	n/a	n/a	-US$126m
Mar 31 2023	n/a	n/a	-US$136m
Dec 31 2022	n/a	n/a	-US$116m
Sep 30 2022	US$6m	US$761k	-US$84m
Jun 30 2022	n/a	n/a	-US$47m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	n/a	n/a	-US$16m
Sep 30 2021	US$2m	US$618k	US$7m
Jun 30 2021	n/a	n/a	-US$144k
Mar 31 2021	n/a	n/a	-US$476k
Dec 31 2020	n/a	n/a	US$2m
Sep 30 2020	US$1m	US$502k	-US$19m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	n/a	n/a	-US$13m
Sep 30 2019	US$800k	US$392k	-US$12m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$22m
Dec 31 2018	n/a	n/a	-US$22m
Sep 30 2018	US$740k	US$383k	-US$24m

Rémunération vs marché: La rémunération totale de Mitch ($USD 4.71M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 474.54K ).

Rémunération et revenus: La rémunération de Mitch a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Mitch Steiner (63 yo)

8.1yrs

Titularisation

US$4,714,041

Compensation

Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Mitchell Steiner	Chairman	8.1yrs	US$4.71m	4.84% € 4.6m
Harry Fisch	Vice Chairman & Chief Corporate Officer	8.1yrs	pas de données	5.47% € 5.2m
Michele Greco	CFO & Chief Administrative Officer	6.9yrs	US$1.55m	0.066% € 63.0k
K. Barnette	Chief Scientific Officer	6.2yrs	US$1.69m	0.0034% € 3.3k
Samuel Fisch	Executive Director of Investor Relations & Corporate Communications	5.6yrs	pas de données	pas de données
Michael Purvis	Executive VP	3.7yrs	pas de données	pas de données
Kevin Gilbert	Executive Vice President of Corporate Development	7.8yrs	pas de données	pas de données
Martin Tayler	Executive Vice President of FC2 Global Operations	no data	US$193.01k	pas de données
Philip Greenberg	Executive VP & Deputy General Counsel	3.8yrs	pas de données	pas de données
Domingo Rodriguez	Executive Vice President of Global Clinical Operations	6.6yrs	pas de données	pas de données
Gary Bird	Executive Vice President of Quality & Regulatory Affairs	5.8yrs	pas de données	pas de données
Jason Davies	Executive VP and GM of UK	2.3yrs	pas de données	pas de données

6.2yrs

Durée moyenne de l'emploi

62.5yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de FMW est chevronnée et expérimentée (6.2 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Mitchell Steiner	Chairman	8.1yrs	US$4.71m	4.84% € 4.6m
Harry Fisch	Vice Chairman & Chief Corporate Officer	8.1yrs	pas de données	5.47% € 5.2m
Louis Aronne	Chief Medical Advisor & Member of the Scientific Advisory	less than a year	pas de données	pas de données
David D. Ho	Chairman of Scientific Advisory Board	1.8yrs	pas de données	pas de données
Andrew Love	Board Observer	8.1yrs	pas de données	pas de données
Robert Schooley	Member of the Scientific Advisory Board	1.4yrs	pas de données	pas de données
Michael Rankowitz	Independent Director	6.7yrs	US$875.93k	0.068% € 65.5k
Xiaoqin Lu	Independent Director	3.5yrs	US$835.75k	0.0067% € 6.4k
Caroline Apovian	Member of Scientific Advisory Board	less than a year	pas de données	pas de données
Mario Eisenberger	Independent Director	8.1yrs	US$795.57k	0% € 0
Grace Hyun	Independent Director	4.3yrs	US$755.39k	0.010% € 9.7k
Erik Swenson	Member of the Scientific Advisory Board	1.4yrs	pas de données	pas de données

3.9yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de FMW sont considérés comme expérimentés (ancienneté moyenne 3.9 ans).

Veru Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Chairman recently sold €227k worth of stock

High number of new and inexperienced directors

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc., Annual General Meeting, Mar 26, 2024

High number of new and inexperienced directors

Recent updates

New minor risk - Market cap size

Veru Inc. Announces Meta-Analysis of Body Composition Data from Older Patients with Obesity Which Supports Potential for Enobosarm to Optimize Weight Loss At Obesityweek

Veru Receives Notification from The Nasdaq Stock Market

Third quarter 2024 earnings released: US$0.075 loss per share (vs US$0.075 loss in 3Q 2023)

Veru Inc. to Report Q3, 2024 Results on Aug 08, 2024

New major risk - Financial position

Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference

Chairman recently sold €227k worth of stock

High number of new and inexperienced directors

Veru Inc. to Report Q2, 2024 Results on May 08, 2024

Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc. announced delayed 10-Q filing

Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study

Veru Receives Non-Compliance Notice From Nasdaq

Veru Inc., Annual General Meeting, Mar 26, 2024

Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss

New major risk - Shareholder dilution

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Third quarter 2023 earnings released: US$0.075 loss per share (vs US$0.28 loss in 3Q 2022)

Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication

Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy

New major risk - Financial position

Third quarter 2023 earnings released: EPS: US$0.072 (vs US$0.28 loss in 3Q 2022)

New minor risk - Market cap size

Veru Inc. to Report Q3, 2023 Results on Aug 10, 2023

High number of new and inexperienced directors

Veru Inc.(NasdaqCM:VERU) dropped from Russell 2000 Dynamic Index

Veru Announces Executive Appointments

Second quarter 2023 earnings released: US$0.48 loss per share (vs US$0.18 loss in 2Q 2022)

Veru Inc. announced that it expects to receive $100 million in funding from Lincoln Park Capital, LLC

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

First quarter 2023 earnings released: US$0.46 loss per share (vs US$0.08 loss in 1Q 2022)

Veru Inc., Annual General Meeting, Mar 28, 2023

Veru Inc. to Report Q1, 2023 Results on Feb 09, 2023

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Veru Inc

Veru Inc. Appoints David D. Ho as Chairman of Its Scientific Advisory Board

Wolf Haldenstein Adler Freeman & Herz LLP Announces Securities Class Action Lawsuit Against Veru Inc

Full year 2022 earnings released: US$1.05 loss per share (vs US$0.097 profit in FY 2021)

Veru Inc. Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc. to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc. Receives Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration

Veru Inc. Appoints Jason Davies as Executive Vice President General Manager of Europe, the Middle East and Africa, Latin America, and Asia Pacific

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.034 loss in 3Q 2021)

Veru Inc. to Report Q3, 2022 Results on Aug 11, 2022

Uk’S Medicines and Healthcare Products Regulatory Agency (Mhra) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized Covid-19 Patients of Veru Inc

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating That Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized Covid-19 Patients

Veru Submits Emergency Use Authorization Application to U.S. FDA for Sabizabulin, Its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients At High Risk for ARDS

Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

Veru Inc. Appoints Joel Batten as Executive Vice President and Head of Its U.S. Infectious Disease Franchise, Effective May 23, 2022

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.038 loss in 2Q 2021)

FDA Has Grants Veru Inc.'s Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study

Veru Inc. Announces Results from Randomized Placebo-Controlled Phase 2 Study of Oral Sabizabulin

Veru Inc.'s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study

Veru Inc. Announces the Presentation of Updated Data from the Phase 1B/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer At the 2022 ASCO Genitourinary Cancers Symposium

Veru Inc. Reports That Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Veru Inc. Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients At High Risk for Acute Respiratory Distress Syndrome

Veru Inc., Annual General Meeting, Mar 29, 2022

Veru Inc., Annual General Meeting, Mar 29, 2022

Investor sentiment improved over the past week

Veru Inc. Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer